Seres Therapeutics的动态

?CDA is so excited for the #ISPORAnnual meeting hosted by ISPOR—The Professional Society for Health Economics and Outcomes Research! We will have 5 presentations, plus our amazing team members Gabriela Samayoa, NEHIR YAPAR, Liz Vivier, and Lauren Isenman, MPH want to meet you! Poster topics: P17 Cardiovascular effect of abiraterone and enzalutamide for #mCRPC CO108 Effect of approved anti-obesity medications in patients with alcohol and #substanceusedisorder CO148 Impact of approved anti-obesity medications on osteoarthritis risk RWD144 Predictive risk score for nonalcoholic steatohepatitis CO177 Effect of newly approved obesity medications on cardiovascular complications #obesitymedications #obesity #NASH #osteoarthritis #oncology #prostatecancer #conference #networking #realworlddata #healthcare #healtheconomics #outcomesresearch #dataanalytics #realworlddata #realworldevidence https://lnkd.in/gk4uA-4w

?? Elevate Your Brand with Endpoints News: A Featured Sponsored Post Opportunity! ???? For all fellow industry enthusiasts and business leaders amplify your brand's presence in the Biotech and Pharma space through a Featured Sponsored Post on Endpoints News. ?? Why Endpoints News? ? Unrivaled Industry Expertise: Navigate the intricate world of biotech and pharma with curated content from seasoned professionals. ? Global Reach: Reach a diverse and influential audience, ensuring your brand resonates across borders. ? Trendsetting Analysis: Stay ahead of the curve with trendsetting analyses, strategic intelligence, and exclusive reports. ?? Our Sponsored Post offers a prime opportunity to showcase your brand, product, or service alongside the latest industry trends. Position your company as a thought leader, reaching a vast and engaged community passionate about driving innovation. ?? Reach out to [email protected] to do your next Featured Sponsored Post!! ?? #Biotech #Pharma #EndpointsNews #SponsoredPost #Innovation #thoughtleadership #pharmaceutical #Healthcare #BrandVisibility #biopharma

Today, we at Basilea reported strong #2023results with a profitability significantly above guidance, whilst substantially expanding our R&D #portfolio. ? ?? Our focus is on #infectiousdiseases, an area with a high medical need worldwide. We develop and bring to market new #antifungals and #antibacterials to help people with severe, life-threatening infections. ? ?? Basilea CEO David Veitch states: “With three #clinical and one preclinical stage compounds added to our portfolio in 2023 and a further preclinical program early in 2024, we have laid the foundation for future growth and are establishing Basilea as the leading anti-infectives company - to serve #patients around the world." ? ?? Watch the full-year 2023 update with David Veitch ?? ? Complete Basilea Full Year Report 2023: https://lnkd.in/ebE3d2h https://lnkd.in/eS2eepuE #basileapharma #basileapharmaceutica

Of course

Of course

Discover our array of short courses (virtual and F2F) on topics in biopharmaceutical statistics at the ISBS Symposium on March 6! All courses are also conveniently available for virtual attendance. Meet our outstanding faculty, including Cong Chen, Ying Yuan, Fariba Khanshan, Rebecca Piccolo, Mark Chang, Dong Xi, Robin Dunn, Jiarui Lu, Mark van der Laan, Susan Gruber, Stefan Konigorski, Hana Lee, and Jie Chen. For further information and registrion see https://lnkd.in/dsYkW7x3 Short courses: * Machine Learning for Clinical Trials and Humanized AI for Future Healthcare and Beyond. (Mark Chang, Boston University) * Dose Optimization: Where the Rubber Meets the Road. (Ying Yuan, M.D. Anderson Cancer Center) * Do you speak statistics? – how do you work as a statistician in a cross-functional team? (Rebecca Piccolo and Fariba Khanshan, Novartis Pharmaceuticals Corporation) * Targeted Learning for generating reliable real-world evidence. Mark van der Laan, University of California at Berkeley and Susan Gruber, TL Revolution) ?* Statistical Considerations for Early-to-Late Transition in Oncology Drug Development. (Cong Chen, Merck) * Causal Inference in Randomized Controlled Trials. (Dong Xi, Gilead Sciences; Robin Dunn, Novartis Pharmaceuticals Corporation; Jiarui Lu, Novartis Pharmaceuticals Corporation) * Next-generation digital N-of-1 trials. (Stefan Konigorski, ?Hasso Plattner Institute for Digital Engineering) * RWE in Drug Development and Regulatory Science. (Hana Lee, FDA and Jie Chen, ECR Global) For further information, schedules and registration see?https://lnkd.in/dsYkW7x3 The 7th International Symposium on Biopharmaceutical Statistics will take place on March 6 – 9, 2024, at Hilton Baltimore Inner Harbor. The symposium is organized by the International Society for Biopharmaceutical Statistics with a theme on “Statistical innovation in the era of integrated evidence for medical product development”. #shortcourse #biostatistics #datascience #regulatoryaffairs #drugdevelopment Cindy Lu Toshimitsu Hamasaki Frank (Xiaoyin) F.

Of course!

?? **Kick-Off Meeting: Embracing Our Moment** ?? Today, as the Beckman Coulter Diagnostics Europe Northern Regions team gathers, we're not just starting a new phase; we're stepping into our moment with a growth mindset. "This Is Our Moment" is more than a theme; it's our collective commitment to learn, grow, and surpass our limits together. Let's use this kick-off to fuel our passion, embrace challenges as opportunities, and remember that every obstacle is a stepping stone to greater achievements. With unity, resilience, and a relentless pursuit of growth, there's no limit to what we can accomplish. #GrowthMindset #ThisIsOurMoment

Collaborating with industry professionals can assist you in your regulatory strategy, design, and prototype iterations as you develop your medical device. It is important to keep in mind a few pitfalls you may encounter as you establish these partnerships. Read this informative article by our managing Director, Gene Parunak, for some best practices to make your collaborations successful.

For early stage companies with promising technologies - the Testa Challenge is a terrific program to showcase your capabilities and get feedback on product - market fit. This years challenge is focused on ADC production. If you have a solution for this important therapeutic class - check out the Testa Challenge to help accelerate your company.